Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates

William J Steinbach, Emmanuel Roilides, David Berman, Jill A Hoffman, Andreas H Groll, Ibrahim Bin-Hussain, Debra L Palazzi, Elio Castagnola, Natasha Halasa, Aristea Velegraki, Christopher C Dvorak, Arunaloke Charkabarti, Lillian Sung, Lara Danziger-Isakov, Catherine Lachenauer, Antonio Arrieta, Katherine Knapp, Mark J Abzug, Christine Ziebold, Thomas LehrnbecherLena Klingspor, Adilia Warris, Kateri Leckerman, Teresa Martling, Thomas J Walsh, Daniel K Benjamin, Theoklis E Zaoutis, International Pediatric Fungal Network

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

BACKGROUND: Candida species are the third most common cause of pediatric health care-associated bloodstream infection in the United States and Europe. To our knowledge, this report from the International Pediatric Fungal Network is the largest prospective, multicenter observational study dedicated to pediatric and neonatal invasive candidiasis.

METHODS: From 2007 to 2011, we enrolled 196 pediatric and 25 neonatal patients with invasive candidiasis.

RESULTS: Non-albicans Candida species predominated in pediatric (56%) and neonatal (52%) age groups, yet Candida albicans was the most common species in both groups. Successful treatment responses were observed in pediatric (76%) and neonatal patients (92%). Infection with Candida parapsilosis led to successful responses in pediatric (92%) and neonatal (100%) patients, whereas infection with Candida glabrata was associated with a lower successful outcome in pediatric patients (55%). The most commonly used primary antifungal therapies for pediatric invasive candidiasis were fluconazole (21%), liposomal amphotericin B (20%) and micafungin (18%). Outcome of pediatric invasive candidiasis was similar in response to polyenes (73%), triazoles (67%) and echinocandins (73%). The most commonly used primary antifungal therapies for neonatal invasive candidiasis were fluconazole (32%), caspofungin (24%) and liposomal amphotericin B (16%) and micafungin (8%). Outcomes of neonatal candidiasis by antifungal class again revealed similar response rates among the classes.

CONCLUSIONS: We found a predominance of non-albicans Candida infection in children and similar outcomes based on antifungal class used. This international collaborative study sets the foundation for large epidemiologic studies focusing on the unique features of neonatal and pediatric candidiasis and comparative studies of therapeutic interventions in these populations.

Original languageEnglish
Pages (from-to)1252-1257
Number of pages6
JournalPediatric Infectious Disease Journal
Volume31
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Invasive Candidiasis
Epidemiologic Studies
Newborn Infant
Pediatrics
Candida
Fluconazole
Candidiasis
caspofungin
Infection
Echinocandins
Candida glabrata
Polyenes
Triazoles
Therapeutics
Cross Infection
Candida albicans
Multicenter Studies
Observational Studies

Keywords

  • Adolescent
  • Antifungal Agents
  • Candida
  • Candidiasis, Invasive
  • Child
  • Child, Preschool
  • Epidemiologic Studies
  • Europe
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • International Cooperation
  • Male
  • Prospective Studies
  • Treatment Outcome
  • United States
  • Journal Article
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

Cite this

Steinbach, W. J., Roilides, E., Berman, D., Hoffman, J. A., Groll, A. H., Bin-Hussain, I., ... International Pediatric Fungal Network (2012). Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatric Infectious Disease Journal, 31(12), 1252-1257. https://doi.org/10.1097/INF.0b013e3182737427

Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. / Steinbach, William J; Roilides, Emmanuel; Berman, David; Hoffman, Jill A; Groll, Andreas H; Bin-Hussain, Ibrahim; Palazzi, Debra L; Castagnola, Elio; Halasa, Natasha; Velegraki, Aristea; Dvorak, Christopher C; Charkabarti, Arunaloke; Sung, Lillian; Danziger-Isakov, Lara; Lachenauer, Catherine; Arrieta, Antonio; Knapp, Katherine; Abzug, Mark J; Ziebold, Christine; Lehrnbecher, Thomas; Klingspor, Lena; Warris, Adilia; Leckerman, Kateri; Martling, Teresa; Walsh, Thomas J; Benjamin, Daniel K; Zaoutis, Theoklis E; International Pediatric Fungal Network.

In: Pediatric Infectious Disease Journal, Vol. 31, No. 12, 12.2012, p. 1252-1257.

Research output: Contribution to journalArticle

Steinbach, WJ, Roilides, E, Berman, D, Hoffman, JA, Groll, AH, Bin-Hussain, I, Palazzi, DL, Castagnola, E, Halasa, N, Velegraki, A, Dvorak, CC, Charkabarti, A, Sung, L, Danziger-Isakov, L, Lachenauer, C, Arrieta, A, Knapp, K, Abzug, MJ, Ziebold, C, Lehrnbecher, T, Klingspor, L, Warris, A, Leckerman, K, Martling, T, Walsh, TJ, Benjamin, DK, Zaoutis, TE & International Pediatric Fungal Network 2012, 'Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates', Pediatric Infectious Disease Journal, vol. 31, no. 12, pp. 1252-1257. https://doi.org/10.1097/INF.0b013e3182737427
Steinbach, William J ; Roilides, Emmanuel ; Berman, David ; Hoffman, Jill A ; Groll, Andreas H ; Bin-Hussain, Ibrahim ; Palazzi, Debra L ; Castagnola, Elio ; Halasa, Natasha ; Velegraki, Aristea ; Dvorak, Christopher C ; Charkabarti, Arunaloke ; Sung, Lillian ; Danziger-Isakov, Lara ; Lachenauer, Catherine ; Arrieta, Antonio ; Knapp, Katherine ; Abzug, Mark J ; Ziebold, Christine ; Lehrnbecher, Thomas ; Klingspor, Lena ; Warris, Adilia ; Leckerman, Kateri ; Martling, Teresa ; Walsh, Thomas J ; Benjamin, Daniel K ; Zaoutis, Theoklis E ; International Pediatric Fungal Network. / Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. In: Pediatric Infectious Disease Journal. 2012 ; Vol. 31, No. 12. pp. 1252-1257.
@article{331ac94efab54adf9178019a04be9ad4,
title = "Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates",
abstract = "BACKGROUND: Candida species are the third most common cause of pediatric health care-associated bloodstream infection in the United States and Europe. To our knowledge, this report from the International Pediatric Fungal Network is the largest prospective, multicenter observational study dedicated to pediatric and neonatal invasive candidiasis.METHODS: From 2007 to 2011, we enrolled 196 pediatric and 25 neonatal patients with invasive candidiasis.RESULTS: Non-albicans Candida species predominated in pediatric (56{\%}) and neonatal (52{\%}) age groups, yet Candida albicans was the most common species in both groups. Successful treatment responses were observed in pediatric (76{\%}) and neonatal patients (92{\%}). Infection with Candida parapsilosis led to successful responses in pediatric (92{\%}) and neonatal (100{\%}) patients, whereas infection with Candida glabrata was associated with a lower successful outcome in pediatric patients (55{\%}). The most commonly used primary antifungal therapies for pediatric invasive candidiasis were fluconazole (21{\%}), liposomal amphotericin B (20{\%}) and micafungin (18{\%}). Outcome of pediatric invasive candidiasis was similar in response to polyenes (73{\%}), triazoles (67{\%}) and echinocandins (73{\%}). The most commonly used primary antifungal therapies for neonatal invasive candidiasis were fluconazole (32{\%}), caspofungin (24{\%}) and liposomal amphotericin B (16{\%}) and micafungin (8{\%}). Outcomes of neonatal candidiasis by antifungal class again revealed similar response rates among the classes.CONCLUSIONS: We found a predominance of non-albicans Candida infection in children and similar outcomes based on antifungal class used. This international collaborative study sets the foundation for large epidemiologic studies focusing on the unique features of neonatal and pediatric candidiasis and comparative studies of therapeutic interventions in these populations.",
keywords = "Adolescent, Antifungal Agents, Candida, Candidiasis, Invasive, Child, Child, Preschool, Epidemiologic Studies, Europe, Female, Humans, Infant, Infant, Newborn, International Cooperation, Male, Prospective Studies, Treatment Outcome, United States, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't",
author = "Steinbach, {William J} and Emmanuel Roilides and David Berman and Hoffman, {Jill A} and Groll, {Andreas H} and Ibrahim Bin-Hussain and Palazzi, {Debra L} and Elio Castagnola and Natasha Halasa and Aristea Velegraki and Dvorak, {Christopher C} and Arunaloke Charkabarti and Lillian Sung and Lara Danziger-Isakov and Catherine Lachenauer and Antonio Arrieta and Katherine Knapp and Abzug, {Mark J} and Christine Ziebold and Thomas Lehrnbecher and Lena Klingspor and Adilia Warris and Kateri Leckerman and Teresa Martling and Walsh, {Thomas J} and Benjamin, {Daniel K} and Zaoutis, {Theoklis E} and {International Pediatric Fungal Network}",
year = "2012",
month = "12",
doi = "10.1097/INF.0b013e3182737427",
language = "English",
volume = "31",
pages = "1252--1257",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates

AU - Steinbach, William J

AU - Roilides, Emmanuel

AU - Berman, David

AU - Hoffman, Jill A

AU - Groll, Andreas H

AU - Bin-Hussain, Ibrahim

AU - Palazzi, Debra L

AU - Castagnola, Elio

AU - Halasa, Natasha

AU - Velegraki, Aristea

AU - Dvorak, Christopher C

AU - Charkabarti, Arunaloke

AU - Sung, Lillian

AU - Danziger-Isakov, Lara

AU - Lachenauer, Catherine

AU - Arrieta, Antonio

AU - Knapp, Katherine

AU - Abzug, Mark J

AU - Ziebold, Christine

AU - Lehrnbecher, Thomas

AU - Klingspor, Lena

AU - Warris, Adilia

AU - Leckerman, Kateri

AU - Martling, Teresa

AU - Walsh, Thomas J

AU - Benjamin, Daniel K

AU - Zaoutis, Theoklis E

AU - International Pediatric Fungal Network

PY - 2012/12

Y1 - 2012/12

N2 - BACKGROUND: Candida species are the third most common cause of pediatric health care-associated bloodstream infection in the United States and Europe. To our knowledge, this report from the International Pediatric Fungal Network is the largest prospective, multicenter observational study dedicated to pediatric and neonatal invasive candidiasis.METHODS: From 2007 to 2011, we enrolled 196 pediatric and 25 neonatal patients with invasive candidiasis.RESULTS: Non-albicans Candida species predominated in pediatric (56%) and neonatal (52%) age groups, yet Candida albicans was the most common species in both groups. Successful treatment responses were observed in pediatric (76%) and neonatal patients (92%). Infection with Candida parapsilosis led to successful responses in pediatric (92%) and neonatal (100%) patients, whereas infection with Candida glabrata was associated with a lower successful outcome in pediatric patients (55%). The most commonly used primary antifungal therapies for pediatric invasive candidiasis were fluconazole (21%), liposomal amphotericin B (20%) and micafungin (18%). Outcome of pediatric invasive candidiasis was similar in response to polyenes (73%), triazoles (67%) and echinocandins (73%). The most commonly used primary antifungal therapies for neonatal invasive candidiasis were fluconazole (32%), caspofungin (24%) and liposomal amphotericin B (16%) and micafungin (8%). Outcomes of neonatal candidiasis by antifungal class again revealed similar response rates among the classes.CONCLUSIONS: We found a predominance of non-albicans Candida infection in children and similar outcomes based on antifungal class used. This international collaborative study sets the foundation for large epidemiologic studies focusing on the unique features of neonatal and pediatric candidiasis and comparative studies of therapeutic interventions in these populations.

AB - BACKGROUND: Candida species are the third most common cause of pediatric health care-associated bloodstream infection in the United States and Europe. To our knowledge, this report from the International Pediatric Fungal Network is the largest prospective, multicenter observational study dedicated to pediatric and neonatal invasive candidiasis.METHODS: From 2007 to 2011, we enrolled 196 pediatric and 25 neonatal patients with invasive candidiasis.RESULTS: Non-albicans Candida species predominated in pediatric (56%) and neonatal (52%) age groups, yet Candida albicans was the most common species in both groups. Successful treatment responses were observed in pediatric (76%) and neonatal patients (92%). Infection with Candida parapsilosis led to successful responses in pediatric (92%) and neonatal (100%) patients, whereas infection with Candida glabrata was associated with a lower successful outcome in pediatric patients (55%). The most commonly used primary antifungal therapies for pediatric invasive candidiasis were fluconazole (21%), liposomal amphotericin B (20%) and micafungin (18%). Outcome of pediatric invasive candidiasis was similar in response to polyenes (73%), triazoles (67%) and echinocandins (73%). The most commonly used primary antifungal therapies for neonatal invasive candidiasis were fluconazole (32%), caspofungin (24%) and liposomal amphotericin B (16%) and micafungin (8%). Outcomes of neonatal candidiasis by antifungal class again revealed similar response rates among the classes.CONCLUSIONS: We found a predominance of non-albicans Candida infection in children and similar outcomes based on antifungal class used. This international collaborative study sets the foundation for large epidemiologic studies focusing on the unique features of neonatal and pediatric candidiasis and comparative studies of therapeutic interventions in these populations.

KW - Adolescent

KW - Antifungal Agents

KW - Candida

KW - Candidiasis, Invasive

KW - Child

KW - Child, Preschool

KW - Epidemiologic Studies

KW - Europe

KW - Female

KW - Humans

KW - Infant

KW - Infant, Newborn

KW - International Cooperation

KW - Male

KW - Prospective Studies

KW - Treatment Outcome

KW - United States

KW - Journal Article

KW - Multicenter Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.1097/INF.0b013e3182737427

DO - 10.1097/INF.0b013e3182737427

M3 - Article

C2 - 22982980

VL - 31

SP - 1252

EP - 1257

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 12

ER -